journal article·2018-05-22

On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA

Jayesh A. Kulkarni, Maria M. Darjuan, Joanne E. Mercer, Sam Chen, Roy van der Meel, Jenifer L. Thewalt, Yuen Yi C. Tam, Pieter R. Cullis

ACS Nano· Volume 12· Issue 5
Publisher page

Abstract

Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure. These systems are formed from lipid mixtures (cationic lipid, distearoylphosphatidylcholine, cholesterol, and PEG-lipid) dissolved in ethanol that is rapidly mixed with siRNA in aqueous buffer at a pH (pH 4) where the ionizable lipid is positively charged. The resulting dispersion is then dialyzed against a normal saline buffer to remove residual ethanol and raise the pH to 7.4 (above the pKa of the cationic lipid) to produce the finished LNP-siRNA systems. Here we provide cryogenic transmission electron microscopy (cryo-TEM) and X-ray evidence that the complexes formed between siRNA and ionizable lipid at pH 4 correspond to tightly packed bilayer structures with siRNA sandwiched between closely apposed monolayers. Further, it is shown that ionizable lipid not complexed to siRNA promotes formation of very small vesicular structures at pH 4 that coalesce to form larger LNP structures with amorphous electron dense cores at pH 7.4. A mechanism of formation of LNP-siRNA systems is proposed whereby siRNA is first sandwiched between closely apposed lipid monolayers at pH 4 and subsequently trapped in these structures as the pH is raised to 7.4, whereas ionizable lipid not interacting with siRNA moves from bilayer structure to adopt an amorphous oil phase located in the center of the LNP as the pH is raised. This model is discussed in terms of previous hypotheses and potential relevance to the design of LNP-siRNA systems.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada

Department of Physics, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada

Integrated Nanotherapeutics, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada

Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands

Funding

Canadian Institutes of Health Research · British Columbia Innovation Council · Natural Sciences and Engineering Research Council of Canada · Nederlandse Organisatie voor Wetenschappelijk Onderzoek

References (25)

Show source-provided references
1. 10.1186/s13073-017-0450-010.1186/s13073-017-0450-0 ↗
2. 10.1016/j.ymthe.2017.03.01310.1016/j.ymthe.2017.03.013 ↗
3. 10.2174/15672011179525617410.2174/156720111795256174 ↗
4. Alnylam and Sanofi Report Positive Topline Results from Apollo Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy. http://www.businesswire.com/news/home/20170920005628/en/, 2017, accessed Jan 11, 2018.
5. 10.1002/anie.20120326310.1002/anie.201203263 ↗
6. 10.1038/nbt.160210.1038/nbt.1602 ↗
7. 10.1038/mtna.2012.2810.1038/mtna.2012.28 ↗
8. 10.1021/jp303267y10.1021/jp303267y ↗
9. 10.1007/s13346-013-0161-z10.1007/s13346-013-0161-z ↗
10. 10.1021/acs.jpcb.5b0289110.1021/acs.jpcb.5b02891 ↗
11. 10.1021/acs.jpcb.7b1079510.1021/acs.jpcb.7b10795 ↗
12. Hirota S. · Biotechniques · 1999 · 27 · 28610.2144/99272bm16 ↗
13. 10.1007/s11095-004-1873-z10.1007/s11095-004-1873-z ↗
14. 10.1021/la204833h10.1021/la204833h ↗
15. 10.1039/C7NR03272B10.1039/C7NR03272B ↗
16. 10.1016/j.jconrel.2005.06.01410.1016/j.jconrel.2005.06.014 ↗
17. 10.1016/j.jconrel.2016.05.05910.1016/j.jconrel.2016.05.059 ↗
18. 10.1073/pnas.78.11.687810.1073/pnas.78.11.6878 ↗
19. 10.1016/S0006-3495(01)76202-910.1016/S0006-3495(01)76202-9 ↗
20. 10.1016/S0005-2736(00)00343-610.1016/S0005-2736(00)00343-6 ↗
21. 10.1016/j.molliq.2016.11.06410.1016/j.molliq.2016.11.064 ↗
22. 10.1039/C5SM00169B10.1039/C5SM00169B ↗
23. 10.1016/j.jconrel.2014.09.02510.1016/j.jconrel.2014.09.025 ↗
24. 10.1038/nbt140210.1038/nbt1402 ↗
25. 10.1038/mtna.2016.6810.1038/mtna.2016.68 ↗